Download PDF
Am J Perinatol 2008; 25(4): 233-237
DOI: 10.1055/s-2008-1066875
© Thieme Medical Publishers

The Effect of Body Mass Index on Therapeutic Response to Bacterial Vaginosis in Pregnancy

Joan M. Mastrobattista1 , Mark A. Klebanoff2 , J. Christopher Carey3 , John C. Hauth4 , Cora A. MacPherson5 , J. Ernest6 , Margaret Cotroneo7 , Kenneth J. Leveno8 , Ronald Wapner9 , Michael Varner10 , Jay D. Iams11 , Atef Moawad12 , Baha M. Sibai13 , Menachem Miodovnik14 , Mitchell Dombrowski15 , Mary J. O'Sullivan16 , J. Peter VanDorsten17 , Oded Langer18 , for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network
  • 1Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Medical School at Houston, Houston, Texas
  • 2Division of Epidemiology, Statistics & Prevention Research National Institute of Child Health and Human Development, Bethesda, Maryland
  • 3University of Colorado School of Medicine, Denver, Colorado
  • 4Department of Obstetrics and Gynecology, University of Alabama, Birmingham, Alabama
  • 5Department of Epidemiology and Biostatistics, The George Washington University Biostatistics Center, Rockville, Maryland
  • 6Department of Obstetrics and Gynecology, Wake Forest University, Winston-Salem, North Carolina
  • 7Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Women's Hospital, Pittsburgh, Pennsylvania
  • 8Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
  • 9Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia Medical University, New York, New York
  • 10Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah
  • 11Department of Obstetrics and Gynecology, Ohio State University, Columbus, Ohio
  • 12Department of Obstetrics and Gynecology, University of Chicago Medical Center, Chicago, Illinois
  • 13Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, Ohio
  • 14Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, D.C.
  • 15Department of Obstetrics and Gynecology, St. John Hospital, Detroit, Michigan
  • 16Department of Obstetrics and Gynecology, University of Miami, Division of Research, Miami, Florida
  • 17Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina
  • 18Department of Obstetrics and Gynecology, St. Luke's-Roosevelt Hospital Center, New York, New York
Further Information

Publication History

Publication Date:
18 March 2008 (online)

    Permissions and Reprints

ABSTRACT

Our objective was to determine the effect of body mass index (BMI) on response to bacterial vaginosis (BV) treatment. A secondary analysis was conducted of two multicenter trials of therapy for BV and Trichomonas vaginalis. Gravida were screened for BV between 8 and 22 weeks and randomized between 16 and 23 weeks to metronidazole or placebo. Of 1497 gravida with asymptomatic BV and preconceptional BMI, 738 were randomized to metronidazole; BMI was divided into categories: < 25, 25 to 29.9, and ≥ 30. Rates of BV persistence at follow-up were compared using the Mantel-Haenszel chi square. Multiple logistic regression was used to evaluate the effect of BMI on BV persistence at follow-up, adjusting for potential confounders. No association was identified between BMI and BV rate at follow-up (p = 0.21). BMI was associated with maternal age, smoking, marital status, and black race. Compared with women with BMI of < 25, adjusted odds ratio (OR) of BV at follow-up were BMI 25 to 29.9: OR, 0.66, 95% CI 0.43 to 1.02; BMI ≥ 30: OR, 0.83, 95% CI 0.54 to 1.26. We concluded that the persistence of BV after treatment was not related to BMI.

KEYWORDS

Body mass index - bacterial vaginosis - pregnancy - treatment

REFERENCES

  • 1 National CDC .Center for Chronic Disease Prevention and Health Promotion: Nutrition and Physical Activity. Defining overweight and obesity. http://Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/defining.htm
    Google Scholar
  • 2 Cheymol G. Drug pharmacokinetics in the obese.  Fundam Clin Pharmacol. 1988;  2(3) 239-256
    PubMedGoogle Scholar
  • 3 Carey J C, Klebanoff M A, Hauth J C et al.. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis.  N Engl J Med. 2000;  342 534-540
    CrossrefPubMedGoogle Scholar
  • 4 Koumans E H, Markowitz L E, Hogan V. for the CDC BV Working Group . Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data.  Clin Infect Dis. 2002;  35(Suppl 2) S152-S172
    CrossrefPubMedGoogle Scholar
  • 5 Hauth J C, Goldenberg R L, Andrews W W, DuBard M B, Copper R L. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis.  N Engl J Med. 1995;  333 1732-1736
    CrossrefPubMedGoogle Scholar
  • 6 Hillier S L, Nugent R P, Eschenbach D A et al.. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant.  N Engl J Med. 1995;  333 1737-1742
    CrossrefPubMedGoogle Scholar
  • 7 Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslei P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis.  Am J Obstet Gynecol. 2003;  189 139-147
    CrossrefPubMedGoogle Scholar
  • 8 Carey J C, Klebanoff M A. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network . What have we learned about vaginal infections and preterm birth?.  Semin Perinatol. 2003;  27 212-216
    CrossrefPubMedGoogle Scholar
  • 9 Kekki M, Kurki T, Kotomaki T, Sintonen H, Paavonen J. Cost-effectiveness of screening and treatment for bacterial vaginosis in early pregnancy among women at low risk for preterm birth.  Acta Obstet Gynecol Scand. 2004;  83 27-36
    CrossrefPubMedGoogle Scholar
  • 10 Tebes C C, Lynch C, Sinnott J. The effect of treating bacterial vaginosis on preterm labor.  Infect Dis Obstet Gynecol. 2003;  11 123-129
    PubMedGoogle Scholar
  • 11 Nugent R P, Krohn M A, Hillier S L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation.  J Clin Microbiol. 1991;  29 297-301
    PubMedGoogle Scholar
  • 12 Chow A W, Jewesson P J. Pharmacokinetics and safety of antimicrobial agents during pregnancy.  Rev Infect Dis. 1985;  7 287-313
    PubMedGoogle Scholar
  • 13 Niebyl J R. Antibiotics and other anti-infective agents in pregnancy and lactation.  Am J Perinatol. 2003;  20 405-414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Tracy J W, Webster Jr L T. Drugs used in the chemotherapy of protozoal infections. In: Hardman JG, Limbird LE, Gilman AG Goodman & Gilman's The Pharmacologic Basis of Therapeutics. 10th ed. New York; McGraw-Hill Medical Publishing Division 2001: 1097-1120
    Google Scholar
  • 15 Workowski K A, Berman S M. Centers for Disease Control and Prevention . Sexually transmitted diseases treatment guidelines 2006.  MMWR Recomm Rep. 2006;  55(No. RR-11) 1-94
    PubMedGoogle Scholar

Joan MastrobattistaM.D. 

Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Health Science Center at Houston

6431 Fannin St., Room 3.274, Houston, TX 77030

      >